Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics - Wikidata - awgldk - TriplyDB

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

http://www.wikidata.org/entity/Q35209594

about

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Concise drug review: pazopanib and axitinib.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Population pharmacokinetic analysis of axitinib in healthy volunteers.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Clinical pharmacology of axitinib.Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.Axitinib for the treatment of advanced renal cell carcinoma.Axitinib plasma pharmacokinetics and ethnic differences.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Axitinib: a review in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.Effect of axitinib on the QT interval in healthy volunteers.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Pharmacokinetics of single-agent axitinib across multiple solid tumor types.Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.Axitinib: in advanced, treatment-experienced renal cell carcinoma.

P2860

Q27028048-A031EFAA-73FC-4F3A-8099-41B81842C532 Q34245458-BB8B7258-123F-4270-B692-CB40EBCBB47E Q34538390-E3665794-3C60-4300-ADE3-BF156CFD3598 Q36182836-AEB6DFA7-57DD-4EAD-9C97-DE6E54D6996E Q36387806-21649626-C597-43C2-965C-BDFE6726E824 Q36391044-6C9F20D3-3793-4395-A1BF-4F7961F01A09 Q37635202-E6610755-0B29-4E89-8257-9F138CDAAF2A Q38014312-ECDD98B9-F7CB-46F4-9DC4-2690C7C6D73A Q38025626-E9130C36-947A-4982-96F0-8900C477B6E1 Q38107175-A4240324-512A-4344-8E86-4EFFAEFC0291 Q38163976-D174A239-4FED-46BF-AB09-047F47D76A35 Q38170397-23DD6429-C8E0-4D38-AA9B-9467B1FAC008 Q38348548-5FDE0842-AA7B-48F2-80E9-BDBE26566C79 Q38514440-9A3B82CB-62D2-4FF1-8B4B-1A565A47EF53 Q38612808-F458AF24-290D-4DEB-89F0-329385887BF9 Q38657787-F2265C8A-FFE9-43A1-B016-4967062ED640 Q41344288-E3874F8A-A602-4AF0-B5CA-8A36D2F0B3F1 Q41496075-708F1509-7CB1-4EF0-BAB5-EC70622E83BB Q41582221-119A9714-0298-488E-9C79-2F15062764DD Q42364404-FAD5F95A-F13B-4613-8709-230D42F58B92 Q44982199-D2F2DDCE-200A-425C-B03E-E776A81DAE5B Q54323723-29016183-DFAF-4A7E-BB4C-F2051B1B222C Q54469002-C47492AE-E72A-4F96-87B7-A1DD74BEC15E

P2860

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

http://www.wikidata.org/entity/Q35209594

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@ast

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@en

type

label

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@ast

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@en

prefLabel

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@ast

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@en

P1433

Q35209594-E48150A9-9852-490E-9B93-42796F4AFDC6

P1476

Q35209594-B168BD36-1982-40C4-9D67-F45BF95F71C3

P2093

Q35209594-1AA6D853-BCFE-4525-8998-2EF00CD80A2A

Q35209594-214B5BC8-54A5-4FA3-8D6A-99632E7020C7

Q35209594-3CDF4CE2-E933-424E-B236-7CA5175EB4C6

Q35209594-3F06E090-352B-41AB-91BD-7945F846BAB5

Q35209594-4B9CA9FD-7723-4BE5-9C08-6168E0B505F0

Q35209594-78615DE5-5A2F-4D6A-82A4-27DD15DCE5B0

Q35209594-95C3119D-7B6D-49C4-9B5A-14F5FDE05D34

Q35209594-9B3E7393-FFBB-4770-87E6-B76E4402B40E

Q35209594-AA605420-AFC4-4E87-8381-7BF5516D34AB

Q35209594-C3B5FE75-C1ED-4E14-908D-FAC6372F6533

P2860

Q35209594-038A8B2B-CFD2-4C32-90FD-97EA6A77284D

Q35209594-441950B5-1955-4F5C-B428-42A7BE2C4002

Q35209594-48679B5C-C7A9-4033-AF6D-5848106B66DF

Q35209594-56B13361-C70D-4D28-84FE-ABEC20472CAA

Q35209594-5ABB1A4A-36D5-45C9-93D0-57A475CE2364

Q35209594-5CA9FD61-9736-45FE-997E-037617678B0F

Q35209594-658D2087-5090-4E62-A342-AFD781FFC292

Q35209594-72F211E4-76B5-408A-BDEE-2137340C743D

Q35209594-93843534-EF22-4ED7-A3BA-32F2D5AD9E09

Q35209594-9A7C83AF-BD3F-419F-9DAF-A72A1E4E5CA9

P2888

Q35209594-1C260760-B3CF-47EB-A235-534E975E1283

P304

Q35209594-6FC894E4-21BC-4E04-8596-E6EF991B574C

P31

Q35209594-F6497ACF-116A-4E68-8C71-C293BAD6717E

P356

Q35209594-36B99105-2F66-4885-9BCC-C0152FA42DA0

P433

Q35209594-EE54A2B8-960B-4BD8-B9E8-25032238D654

P478

Q35209594-F3143DCB-9102-45B3-9460-361D33B0AD29

P577

Q35209594-F74C85F2-B4FE-452B-86F9-F4FD6C5E50E3

P5875

Q35209594-4BBA6DB0-B01F-4FC8-9594-2FD99F5D070B

P698

Q35209594-E476D7E3-F1A4-4DD8-972C-E359BB0762ED

P932

Q35209594-B6C4D44E-C7C3-46EB-8B17-93617B2ECA2C

P356

S10637-010-9477-4

P1433

Investigational New Drugs

P1476

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

@en

P2093

Brian Hee

http://www.w3.org/2001/XMLSchema#string

Christine W Alvey

http://www.w3.org/2001/XMLSchema#string

Ernesto Fuentes

http://www.w3.org/2001/XMLSchema#string

Grace Ni

http://www.w3.org/2001/XMLSchema#string

Matthew Green

http://www.w3.org/2001/XMLSchema#string

Melvin Toh

http://www.w3.org/2001/XMLSchema#string

Michael A Tortorici

http://www.w3.org/2001/XMLSchema#string

Robert R Labadie

http://www.w3.org/2001/XMLSchema#string

S V Rahavendran

http://www.w3.org/2001/XMLSchema#string

Thomas Marbury

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

The Simcyp population-based ADME simulator

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Transection of the oesophagus for bleeding oesophageal varices.

A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Protein binding and kinetics of drugs in liver diseases.

P2888

s10637-010-9477-4

P304

1370-1380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-010-9477-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44903243

http://www.w3.org/2001/XMLSchema#string

P698

20596748

http://www.w3.org/2001/XMLSchema#string

P932

3171651

http://www.w3.org/2001/XMLSchema#string